Similarly, AKR1C3 facilitates hepatocellular carcinoma adaptation to sorafenib by promoting lipid droplet biogenesis, inhibiting autophagy, and reprogramming metabolic circuits [40]. Here, AKR1C3 is linked to hepatocellular carcinoma.